We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.91%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$603M
AUM Growth
-$14M
(-2.3%)
Cap. Flow
-$37.8M
Cap. Flow
% of AUM
-6.28%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
2
Increased
–
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$12.6M |
| 2 |
SYBX
Synlogic
SYBX
|
+$7.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$1.7B
| $384M | 63.7% |
3,688,448
| – | – |
|
2
Collegium Pharmaceutical
COLL
$820M
| $48.2M | 8% |
1,887,332
| – | – |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $39.1M | 6.49% |
2,600,014
| – | – |
|
4
Iovance Biotherapeutics
IOVA
$3.74B
| $37M | 6.14% |
2,188,331
| – | – |
|
|
ALNA
5
DELISTED
Allena Pharmaceuticals
ALNA
| $36.7M | 6.09% |
3,330,373
| – | – |
|
|
ALPN
6
DELISTED
Alpine Immune Sciences Inc
ALPN
| $17.6M | 2.92% |
2,199,011
| – | – |
|
|
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $16.8M | 2.79% |
202,803
| – | – |
|
|
ARMO
8
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| $11.2M | 1.86% |
+300,000
| New | +$12.6M |
|
|
SYBX
9
DELISTED
Synlogic
SYBX
| $6.88M | 1.14% |
+48,912
| New | +$7.58M |
|
|
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
| $5.25M | 0.87% |
65,613
| – | – |
|
|
RXDX
11
DELISTED
Ignyta, Inc.
RXDX
| – | – |
-2,173,693
| Closed | -$58M |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q1 2018 Portfolio in Review
As of Q1 2018, Frazier Management held 11 positions worth $603M, down 2.3% from $617M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Frazier Management withdrew a net $37.8M in Q1 2018, closing 1 position. Its most notable exit was Ignyta, Inc., an estimated $58M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Frazier Management opened a new position in ARMO BioSciences, Inc. Common Stock worth $11.2M.
- Frazier Management's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 300,000 shares worth $11.2M.
- Frazier Management fully exited Ignyta, Inc. in Q1 2018, selling an estimated $58M.
- Frazier Management's ten largest holdings make up 100% of its $603M portfolio in Q1 2018.
- Frazier Management opened 2 new positions and closed 1 in Q1 2018.
- Frazier Management's portfolio value fell 2.3% quarter-over-quarter to $603M.
Based on Frazier Management's 13F filing for Q1 2018, filed 14 May 2018.